Yes, infliximab is a biologic drug. Sold under the brand name Remicade (along with several biosimilar versions), it belongs to a class of biologics called monoclonal antibodies. These are large, complex proteins made from living cells rather than synthesized through chemical reactions like conventional pills. Infliximab specifically targets a protein in the body called TNF-alpha that drives inflammation, making it a cornerstone treatment for several autoimmune conditions.
What Makes Infliximab a Biologic
The distinction between a biologic and a conventional drug comes down to how it’s made and how complex it is. Standard medications like ibuprofen or methotrexate are small molecules built through chemical processes. Biologics, by contrast, are manufactured using living cells. Infliximab is produced by a recombinant cell line cultured through continuous perfusion, then purified through multiple steps that include measures to inactivate and remove viruses. The final product is a protein with a molecular weight of about 149,100 daltons, roughly a thousand times heavier than aspirin.
Infliximab is classified as a “chimeric” monoclonal antibody, meaning it’s built from two species’ genetic material. The portion that locks onto its target comes from mouse-derived sequences, while the structural backbone is human. This hybrid design allows the drug to precisely recognize and bind TNF-alpha while remaining mostly compatible with the human immune system. Because it’s a protein, the prepared solution is colorless to light yellow and slightly opalescent, and it can only be delivered by infusion, not taken as a pill (stomach acid would destroy it).
How Infliximab Works in the Body
TNF-alpha is one of the immune system’s main alarm signals. In autoimmune diseases, the body produces too much of it, triggering chronic inflammation that damages the gut lining, joints, skin, or spine depending on the condition. Infliximab works by binding directly to TNF-alpha and neutralizing it before it can activate inflammatory pathways.
What sets infliximab apart from some other TNF-blocking drugs is how strongly it attaches to the form of TNF-alpha that sits on the surface of immune cells, called transmembrane TNF-alpha. Research published in Gastroenterology found that infliximab binds to this surface-bound form with higher avidity than etanercept, another TNF blocker. This stronger binding triggers a process called apoptosis, essentially programming overactive immune cells in inflamed tissue to self-destruct. That mechanism helps explain why infliximab is particularly effective in conditions like Crohn’s disease, where these activated immune cells accumulate in the gut wall.
Conditions Infliximab Treats
Infliximab has FDA approval for six autoimmune conditions:
- Crohn’s disease (moderate to severe, including fistulizing disease)
- Ulcerative colitis (moderate to severe)
- Rheumatoid arthritis (moderate to severe)
- Ankylosing spondylitis (inflammatory spinal arthritis)
- Psoriatic arthritis
- Plaque psoriasis (chronic severe cases)
Updated 2025 guidelines from the American College of Gastroenterology continue to position infliximab as first-line therapy for fistulizing Crohn’s disease. The same guidelines also recommend it for postoperative prevention in high-risk Crohn’s patients and now include a newer subcutaneous formulation as a maintenance option, giving some patients the possibility of self-injecting at home rather than visiting an infusion center.
What the Infusion Process Looks Like
For most conditions, treatment starts with three loading doses given as intravenous infusions at weeks zero, two, and six. After that, maintenance infusions typically happen every eight weeks, though the interval is every six weeks for ankylosing spondylitis. Each infusion takes about two hours, and you’ll usually stay for observation afterward to watch for reactions.
Dosing is weight-based. Most conditions call for 5 mg per kilogram of body weight per infusion. Rheumatoid arthritis uses a lower dose of 3 mg/kg. Your treatment team may adjust the dose or shorten the interval if you lose response over time, a common consideration with biologic therapies.
Key Safety Considerations
Because infliximab suppresses part of the immune system, it carries a boxed warning (the FDA’s most serious safety label) for two main risks: serious infections and certain cancers.
On the infection side, suppressing TNF-alpha can reactivate latent tuberculosis. You’ll be tested for TB before starting treatment and periodically during therapy. Treating latent TB before beginning infliximab has been shown to reduce the risk of reactivation. Beyond TB, the drug increases susceptibility to bacterial, viral, and fungal infections throughout the body. If a serious infection develops during treatment, the drug is typically stopped.
The cancer concern involves lymphoma and other malignancies that have been reported in patients on TNF blockers, particularly in children and adolescents. A rare but aggressive form called hepatosplenic T-cell lymphoma has been reported after marketing, mostly in adolescent and young adult males being treated for Crohn’s disease or ulcerative colitis. These risks are uncommon but factor into the decision to start treatment, especially in younger patients.
Biosimilars and Availability
Because infliximab is a biologic, it can’t be replicated through generic manufacturing the way a small-molecule drug can. Instead, near-identical versions called biosimilars go through their own approval process to demonstrate they match the original in safety and effectiveness. Several infliximab biosimilars are now available, and they’ve significantly lowered the cost of treatment. Your doctor or insurance plan may recommend a biosimilar version, which works the same way as the branded Remicade product but is typically less expensive.